SNWV - SANUWAVE Health, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.3049
+0.0049 (+1.63%)
At close: 3:50PM EST
Stock chart is not supported by your current browser
Previous Close0.3000
Open0.3000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2800 - 0.3050
52 Week Range0.1000 - 0.6400
Volume46,000
Avg. Volume134,184
Market Cap47.422M
Beta (3Y Monthly)-2.31
PE Ratio (TTM)N/A
EPS (TTM)-0.0850
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    SANUWAVE Celebrates Prolific Success From Increased Patent Activity This Year

    ·       U.S. patent number US 10,053,376 entitled “Acoustic Pressure Shock Wave Devices and Methods for Fluids Processing” was issued on August 28, 2018 and has an effective life through December 2036.  The patent includes twenty claims relating to the use of shockwaves for removing particulate matter from contaminated waters. ·       U.S. patent number US 10,058,340 entitled “Extracorporeal Pressure Shock Wave Devices with Multiple Reflectors and Methods for Using These Devices” was issued on August 28, 2018 and has an effective life through November 2032.  The patent includes twenty claims relating to the use of extracorporeal shockwaves, generated from multiple reflectors for cardiovascular applications, orthopedic afflictions, infection elimination, and stem cells stimulation, proliferation and differentiation.

  • GlobeNewswire9 days ago

    SANUWAVE Announces Attendance at the 5th Annual Innovations In Wound Healing Symposium, Key West, December 6-9, 2018

    SUWANEE, GA, Dec. 07, 2018 -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) SANUWAVE is excited to announce attendance at the 5th annual Innovations In Wound Healing.

  • GlobeNewswire12 days ago

    SANUWAVE Announces Peer Review Article Published in Journal of Wound Care (Dec. 2018): Extracorporeal Shock Wave Technology (ESWT) as Compared to Standard of Care in DFUs

    SUWANEE, GA, Dec. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, announces the publication of the research that investigated the effects of dermaPACE® System (an Extracorporeal Shock Wave Technology (ESWT)) compared with Standard of Care in Diabetic Foot Ulcers (DFUs). The peer reviewed article, titled “Diabetic foot ulcer treatment with focused shockwave therapy: two multicentre prospective, controlled, double-blinded, randomised phase III clinical trials,” by Robert Snyder, DPM, Robert Galiano M.D., Perry Mayer MB, Oscar Alvarez PhD, Lee C. Rogers DPM, will be published in the December 2018 issue of the Journal of Wound Care.

  • Zacks Small Cap Research13 days ago

    SNWV: Robust International Revenue Growth, U.S. Should Benefit from Tracking Code

    Q3 Results, Operational Update: Robust Int’l Revenue, U.S. Should Benefit from Tracking Code…. SANUWAVE (SNWV) reported financial results and provided a business update (on two consecutive Q3 earnings calls). Revenue has now grown on a sequential basis for the fifth consecutive quarter and is trending at an annual run rate of more than $3M.

  • GlobeNewswire26 days ago

    SANUWAVE Health Reports Record Third Quarter Revenue

    Total Revenue Increase of 269%;Initial US treatments have begun, New President, Shri Parikh, to Discuss on Conference Call at 10 am SUWANEE, Ga., Nov. 20, 2018 -- via.

  • GlobeNewswirelast month

    SANUWAVE Health to Hold Third Quarter 2018 Financial Results and Business Update Call on Thursday, November 15, 2018

    SUWANEE, GA, Nov. 14, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) announced today that the Company will release financial results for the third quarter ended September 30, 2018 this week. The Company will also host a conference call on Thursday, November 15, 2018, beginning at 10AM Eastern Time to discuss the third quarter financial results, provide a business update and answer questions. SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures.

  • GlobeNewswire2 months ago

    Premier Shockwave to Exhibit at Desert Foot Annual Multi-Disciplinary Limb Salvage Conference in Phoenix, AZ, November 7-10 at Booth #61

    SUWANEE, GA, Oct. 31, 2018 -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) and Premier Shockwave, Inc. are pleased to announce that Premier Shockwave will exhibit at.

  • GlobeNewswire2 months ago

    SANUWAVE Announces Exhibition at Fall SAWC 2018 Including a Poster and Three Presentations - Visit us at Booth #441

    SUWANEE, GA , Oct. 17, 2018 -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce that the company will exhibit at SAWC (Symposium on Advanced.

  • GlobeNewswire2 months ago

    Premier Shockwave CEO and President, A. Michael Stolarski, Discusses Science Behind dermaPACE® on American Indian Living Radio

    SUWANEE, GA, Oct. 11, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) and Premier Shockwave, Inc. are pleased to announce that Premier Shockwave, Inc. and the dermaPACE® device were featured on American Indian Living Radio during the September 24, 2018 broadcast hosted by Dr. David DeRose. Dr. DeRose began the interview by saying that he had never heard of using shock waves to treat diabetic foot ulcers (DFUs) but had looked at some of the scientific photographs and found them to be “pretty impressive stuff.” Stolarski replied that the treatment was “very legitimate” and noted that the device was recently cleared by the FDA on December 28, 2017.  Stolarski continued by detailing the 336-patient double-blinded, randomly-controlled FDA study conducted without physician assisted closure and without the assistance of antimicrobial or antibacterial assistance which achieved statistically significant rates of complete closure by 20 weeks in DFUs treated with dermaPACE® in conjunction with standard of care as compared to wounds treated with only standard of care.

  • Zacks Small Cap Research3 months ago

    SNWV: Revenue Momentum Continues As Does International Expansion. Two New JVs Signed in Q2

    Q2 Results, Operational Update: International Expansion Continues With 2 New JVs Signed in Q2…. Revenue continues to gain momentum, reflecting initial contribution from the recent U.S. launch and, to a greater degree, SNWV’s ever-expanding international footprint. Q2 revenue of $453k, which is the second-highest quarterly revenue in company history, was up more than 300% from the prior year and 32% from Q1 ’18.

  • Zacks Small Cap Research7 months ago

    SNWV: Several Milestones in Q1 Including Initial U.S. dermaPACE Revenue

    Q1 ’18 marked a milestone for SNWV - or more accurately, marked three milestones. The $344k of revenue is the highest Q1 revenue in company history and it included U.S. dermaPACE revenue – which is another first. U.S. dermaPACE revenue relates to the first shipments to Premier Shockwave.